Akoya Biosciences (AKYA)
(Delayed Data from NSDQ)
$3.82 USD
+0.01 (0.26%)
Updated Apr 25, 2024 04:00 PM ET
After-Market: $3.83 +0.01 (0.26%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth C Momentum C VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
AKYA 3.82 +0.01(0.26%)
Will AKYA be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for AKYA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for AKYA
Akoya Biosciences (AKYA) Reports Q4 Loss, Tops Revenue Estimates
Beat the Market the Zacks Way: Freshpet, NVIDIA, QuantaSing in Focus
AKYA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Has Acumen Pharmaceuticals (ABOS) Outpaced Other Medical Stocks This Year?
Acadia Pharmaceuticals (ACAD) Q4 Earnings Lag Estimates
Are Medical Stocks Lagging Aclaris Therapeutics (ACRS) This Year?
Other News for AKYA
Akoya to Report First Quarter 2024 Financial Results on May 13th, 2024
Piper Sandler Keeps Their Buy Rating on Akoya Biosciences (AKYA)
Akoya Biosciences Showcases Spatial Biology 2.0 Solutions at AACR Annual Meeting with Case Studies Demonstrating Unprecedented Speed and Scale
Akoya Biosciences showcases spatial biology 2.0 solutions at AACR meeting
Cytek Biosciences: Undisputed Next-Gen Flow Cytometry Leader